Table 2: Type of infection, duration of treatment and clinical efficacy of tigecycline.
Type of infections N (%) Admitted to ICU, N (%) Duration of treatment, days Median (range) Positive response N(%) Negative response N(%) Mortality N(%)
Intra-abdominal infections 50(16) 23(46) 23(46) 27(54) 19(38)
Secondary peritonitis 9 4 14(4~27) 6 3 3
Tertiary peritonitis 11 12 10(4~28) 0 11 7
others 30 7 11(4~45) 17 13 9
Lower respiratory tract infections 101(33) 82(81) 18(18) 83(82) 48(48)
Pneumonia complicated with bloodstream infections 11 4 6(3~21) 0 11 6
Hospital-acquired pneumonia 89 78 10(4~36) 17 72 42
Community-acquired pneumonia 1 0 15 1 0 0
Skin and skin structure infections 137(44) 15(11) 101(74) 36(26) 12(9)
Surgical wounds 5 2 10(4~19) 5 0 0
Complicated skin and skin structure 132 13 10(3~42) 96 36 12
Urinary tract infection 17(6) 6(35) 7(3~23) 7(41) 10(59) 4(24)
Other infections 4(1) 1(25) 2(50) 2(50) 1(25)
Neuropenia 3 1 16(16~17) 1 2 1
Otitis media 1 0 5 1 0 0
Total 309 127(41) 10(3~45) 151(49%) 158(51%) 84(27%)